Loading...

Humana

DB:47H
Snowflake Description

Very undervalued with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
47H
DB
SEK3B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Humana AB (publ), together with its subsidiaries, provides individual and family care services for children, adolescents, and adults in Sweden, Norway, Denmark, and Finland. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Humana has significant price volatility in the past 3 months.
47H Share Price and Events
7 Day Returns
-1.8%
DB:47H
-2.6%
DE Healthcare
-2.3%
DE Market
1 Year Returns
-14.7%
DB:47H
-25.9%
DE Healthcare
-11.5%
DE Market
47H Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Humana (47H) -1.8% -7.7% -22.5% -14.7% -36.8% -
DE Healthcare -2.6% -4.8% -3.2% -25.9% -23% 32.4%
DE Market -2.3% -4.9% 0.8% -11.5% 5.7% 6.6%
1 Year Return vs Industry and Market
  • 47H outperformed the Healthcare industry which returned -25.9% over the past year.
  • 47H underperformed the Market in Germany which returned -11.5% over the past year.
Price Volatility
47H
Industry
5yr Volatility vs Market
Related Companies

47H Value

 Is Humana undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Humana to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Humana.

DB:47H Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:47H
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 22%) (115.81%))
1.207
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.21
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.207 * 5.96%)
7.42%

Discounted Cash Flow Calculation for DB:47H using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Humana is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:47H DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 7.42%)
2019 -513.00 Analyst x1 -477.57
2020 357.00 Analyst x2 309.39
2021 389.00 Analyst x2 313.83
2022 412.64 Est @ 6.08% 309.91
2023 430.48 Est @ 4.32% 300.98
2024 443.80 Est @ 3.09% 288.86
2025 453.72 Est @ 2.23% 274.92
2026 461.12 Est @ 1.63% 260.11
2027 466.71 Est @ 1.21% 245.07
2028 470.99 Est @ 0.92% 230.24
Present value of next 10 years cash flows SEK2,055.73
DB:47H DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK470.99 × (1 + 0.23%) ÷ (7.42% – 0.23%)
SEK6,564.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK6,564.02 ÷ (1 + 7.42%)10
SEK3,208.74
DB:47H Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK2,055.73 + SEK3,208.74
SEK5,264.47
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK5,264.47 / 53.14
SEK99.07
DB:47H Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:47H represents 0.09191x of OM:HUM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09191x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 99.07 x 0.09191
€9.11
Value per share (EUR) From above. €9.11
Current discount Discount to share price of €5.00
= -1 x (€5.00 - €9.11) / €9.11
45.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Humana is available for.
Intrinsic value
45%
Share price is €5 vs Future cash flow value of €9.11
Current Discount Checks
For Humana to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Humana's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Humana's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Humana's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Humana's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:47H PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK4.61
OM:HUM Share Price ** OM (2019-05-24) in SEK SEK54.4
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 37.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 20.2x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Humana.

DB:47H PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:HUM Share Price ÷ EPS (both in SEK)

= 54.4 ÷ 4.61

11.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Humana is good value based on earnings compared to the DE Healthcare industry average.
  • Humana is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Humana's expected growth come at a high price?
Raw Data
DB:47H PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 11.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
12.9%per year
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.4x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

DB:47H PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 11.8x ÷ 12.9%

0.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Humana is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Humana's assets?
Raw Data
DB:47H PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK41.17
OM:HUM Share Price * OM (2019-05-24) in SEK SEK54.4
Germany Healthcare Industry PB Ratio Median Figure of 11 Publicly-Listed Healthcare Companies 1.5x
Germany Market PB Ratio Median Figure of 577 Publicly-Listed Companies 1.77x
DB:47H PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:HUM Share Price ÷ Book Value per Share (both in SEK)

= 54.4 ÷ 41.17

1.32x

* Primary Listing of Humana.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Humana is good value based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess Humana's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Humana has a total score of 6/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

47H Future Performance

 How is Humana expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Humana expected to grow at an attractive rate?
  • Humana's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Humana's earnings growth is positive but not above the Germany market average.
  • Humana's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:47H Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:47H Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 12.9%
DB:47H Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 7.2%
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 9.2%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:47H Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:47H Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 8,389 542 336 2
2020-12-31 7,993 507 305 2
2019-12-31 7,434 437 254 2
DB:47H Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 6,774 425 245
2018-12-31 6,714 332 246
2018-09-30 6,600 396 228
2018-06-30 6,566 345 197
2018-03-31 6,541 216 199
2017-12-31 6,542 241 194
2017-09-30 6,635 -185 195
2017-06-30 6,684 -153 241
2017-03-31 6,540 -143 226
2016-12-31 6,362 -161 148
2016-09-30 6,140 255 139
2016-06-30 5,868 202 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Humana's earnings are expected to grow by 12.9% yearly, however this is not considered high growth (20% yearly).
  • Humana's revenue is expected to grow by 7.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:47H Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Humana Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:47H Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 6.32 6.83 5.81 2.00
2020-12-31 5.73 6.13 5.33 2.00
2019-12-31 4.77 5.18 4.36 2.00
DB:47H Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 4.61
2018-12-31 4.63
2018-09-30 4.29
2018-06-30 3.71
2018-03-31 3.74
2017-12-31 3.65
2017-09-30 3.67
2017-06-30 4.53
2017-03-31 4.25
2016-12-31 2.87
2016-09-30 2.80
2016-06-30 -0.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Humana is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Humana's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Humana has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

47H Past Performance

  How has Humana performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Humana's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Humana has delivered over 20% year on year earnings growth in the past 5 years.
  • Humana's 1-year earnings growth is less than its 5-year average (23.1% vs 42.4%)
  • Humana's earnings growth has exceeded the DE Healthcare industry average in the past year (23.1% vs 4.7%).
Earnings and Revenue History
Humana's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Humana Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:47H Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 6,774.00 245.00 264.00
2018-12-31 6,714.00 246.00 264.00
2018-09-30 6,600.00 228.00 212.00
2018-06-30 6,566.00 197.00 212.00
2018-03-31 6,541.00 199.00 212.00
2017-12-31 6,542.00 194.00 212.00
2017-09-30 6,635.00 195.00 218.00
2017-06-30 6,684.00 241.00 218.00
2017-03-31 6,540.00 226.00 218.00
2016-12-31 6,362.00 148.00 218.00
2016-09-30 6,140.00 139.00 157.00
2016-06-30 5,868.00 -11.00 157.00
2016-03-31 5,713.00 -53.00 157.00
2015-12-31 5,593.00 28.00 157.00
2014-12-31 5,065.00 38.00 129.00
2013-12-31 3,489.00 111.00 58.00
2012-12-31 2,981.66 43.98 164.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Humana has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Humana used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • Humana's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Humana's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Humana has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

47H Health

 How is Humana's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Humana's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Humana's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Humana's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Humana's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Humana Company Filings, last reported 1 month ago.

DB:47H Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 2,206.00 3,348.00 420.00
2018-12-31 2,147.00 1,892.00 514.00
2018-09-30 2,092.00 1,915.00 511.00
2018-06-30 1,994.00 1,925.00 507.00
2018-03-31 1,966.00 1,993.00 497.00
2017-12-31 1,891.00 2,025.00 584.00
2017-09-30 1,856.00 2,022.00 432.00
2017-06-30 1,785.00 2,030.00 468.00
2017-03-31 1,764.00 2,045.00 359.00
2016-12-31 1,726.00 2,082.00 465.00
2016-09-30 1,697.00 1,724.00 395.00
2016-06-30 1,567.00 1,707.00 393.00
2016-03-31 1,527.00 1,464.00 631.00
2015-12-31 1,093.00 1,675.00 501.00
2014-12-31 986.00 1,774.00 244.00
2013-12-31 853.00 650.00 291.00
2012-12-31 628.48 565.43 196.78
  • Humana's level of debt (151.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (105% vs 151.8% today).
  • Debt is not well covered by operating cash flow (12.7%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 7.1x coverage).
X
Financial health checks
We assess Humana's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Humana has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

47H Dividends

 What is Humana's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.29%
Current annual income from Humana dividends. Estimated to be 3.05% next year.
If you bought €2,000 of Humana shares you are expected to receive €26 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Humana's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.45%).
  • Humana's dividend is below the markets top 25% of dividend payers in Germany (3.89%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:47H Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:47H Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 2.00 2.00
2020-12-31 1.80 2.00
2019-12-31 1.19 2.00
DB:47H Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-03-28 0.700 1.175
2018-05-16 0.600 0.992
2017-05-18 0.500 0.900

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Humana has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Humana only paid a dividend in the past 2 years.
Current Payout to shareholders
What portion of Humana's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (6.6x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.3x coverage).
X
Income/ dividend checks
We assess Humana's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Humana afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Humana has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

47H Management

 What is the CEO of Humana's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rasmus Nerman
COMPENSATION SEK3,604,000
AGE 40
TENURE AS CEO 4.3 years
CEO Bio

Mr. Rasmus Nerman has been Chief Executive Officer and President of Humana AB since 2015. Mr. Nerman served as Deputy Chief Executive Officer of Humana. He served as Business Area Manager in Humana Individ & Familj. He served as Chief Executive Officer of INOM – Innovativ Omsorg i Norden AB. He served as Management consultant of mainly within healthcare services, Boston Consulting Group. He serves as Board member of Vårdföretagarna Individ & Familj. Mr. Nerman holds MBA from Stockholm School of Economics and M.Sc. in International Management from CEMS MIM.

CEO Compensation
  • Rasmus's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rasmus's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Humana management team in years:

4.3
Average Tenure
48
Average Age
  • The tenure for the Humana management team is about average.
Management Team

Rasmus Nerman

TITLE
CEO & President
COMPENSATION
SEK4M
AGE
40
TENURE
4.3 yrs

Ulf Bonnevier

TITLE
CFO & VP
AGE
54
TENURE
7.3 yrs

Anna Sönne

TITLE
Head of Investor Relations

Helena Pharmanson

TITLE
Director of Marketing & Communication
AGE
52
TENURE
9.3 yrs

Anna Skablova

TITLE
Director of Human Resource
AGE
48
TENURE
2.3 yrs

Johanna Rastad

TITLE
Head of Business Development
AGE
38
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Humana board of directors in years:

6.8
Average Tenure
55
Average Age
  • The tenure for the Humana board of directors is about average.
Board of Directors

Sören Mellstig

TITLE
Chair of the Board
AGE
67

Lloyd Perry

TITLE
Director
AGE
53
TENURE
11.3 yrs

Magdalena Gerger

TITLE
Director
AGE
54

Fredrik Strömholm

TITLE
Director
AGE
53

Per Granath

TITLE
Director
COMPENSATION
SEK242K
AGE
64
TENURE
13.3 yrs

Kirsi Komi

TITLE
Director
COMPENSATION
SEK155K
AGE
55
TENURE
2.3 yrs

Monica Lingegård

TITLE
Director
COMPENSATION
SEK249K
AGE
56
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Humana insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. May 19 Buy Rasmus Nerman Individual 22. May 19 22. May 19 9,230 €5.06 €46,667
14. May 19 Buy Kirsi Komi Individual 10. May 19 10. May 19 4,540 €5.51 €24,863
15. Mar 19 Sell Zirkona AB Company 15. Mar 19 15. Mar 19 -1,000,000 €6.69 €-6,688,412
26. Nov 18 Buy Helen Gillstedt Individual 26. Nov 18 26. Nov 18 1,000 €5.68 €5,676
08. Jun 18 Sell Ulrika Östlund Individual 07. Jun 18 07. Jun 18 -1,500 €6.05 €-9,072
X
Management checks
We assess Humana's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Humana has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

47H News

Simply Wall St News

47H Company Info

Description

Humana AB (publ), together with its subsidiaries, provides individual and family care services for children, adolescents, and adults in Sweden, Norway, Denmark, and Finland. The company operates through four segments: Individual & Family, Personal Assistance, Elderly Care, and Other Nordics. The Individual & Family segment provides care and treatment in psychiatry and psychosocial change processes through residential care homes, temporary and regular family homes, special service housing, outpatient care and assisted living homes, and specially adapted housing. The Personal Assistance segment provides care services and assistance to individuals with functional impairments. The Elderly Care segment consists of elderly housing, as well as provides day care, flats adapted for the elderly, meeting places, and family member services. The Other Nordics segment provides care and treatment for children, adolescents, and adults by offering various forms of housing, family homes, outpatient care and other support services; and offers personal assistance and special services housing. Humana AB (publ) was founded in 2001 and is headquartered in Stockholm, Sweden.

Details
Name: Humana AB (publ)
47H
Exchange: DB
Founded: 2001
SEK270,078,383
53,140,064
Website: http://www.humana.se
Address: Humana AB (publ)
Warfvinges väg 39,
7th floor,
Stockholm,
Stockholm County, 112 51,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM HUM Ordinary B Shares OMX Nordic Exchange Stockholm SE SEK 22. Mar 2016
DB 47H Ordinary B Shares Deutsche Boerse AG DE EUR 22. Mar 2016
LSE 0RF7 Ordinary B Shares London Stock Exchange GB SEK 22. Mar 2016
Number of employees
Current staff
Staff numbers
9,481
Humana employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 22:12
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/24
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.